一、临床肿瘤杂志（2023年第73卷第4期）
July/August 2023 - Volume 73 - Issue 34（2023年7/8月第73卷第4期）
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2023/73/4 

PERSPECTIVES（观点）
1.临床医师需要及时关注多重用药问题
(Clinicians need to stay current with polypharmacy concerns)
作者：Mike Fillon

二、柳叶刀（2023年第402卷第10400-10403期）
（一）05 August 2023 - Volume 402 - Issue 10400（2023年8月5日第402卷第10400期）
https://www.thelancet.com/journals/lancet/issue/vol402no10400/PIIS0140-6736(23)X0031-2

COMMENT（评论）
1.阿替利珠单抗用于不适合含铂双药治疗的晚期非小细胞肺癌患者
(Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible)
作者：Hazel O'Sullivan, Sanjay Popat* (Department of Medical Oncology, Cork University Hospital, Ireland; Section of Clinical Trials, Institute of Cancer Research, UK)

2.每日一次口服非肽类药物orforglipron，与已建立的基于多肽的注射剂GLP-1受体激动剂之间的竞争
(Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists)
作者：Michael A Nauck* (GermanyInstitute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Germany)

ARTICLES（文章）
3.不适合含方案(IPSOS)治疗条件下，非小细胞肺癌患者的一线阿替利珠单抗单药治疗与单药化疗：一项3期、全球性、多中心、开放标签、随机对照研究
(First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study)
作者：Siow Ming Lee* (Department of Oncology, University College London Hospitals NHS Foundation Trust, CRUK Lung Cancer Centre of Excellence and UCL Cancer Institute, UK)

4.口服orforglipron在2型糖尿病患者中的有效性和安全性：一项多中心、随机、剂量反应、2期研究
(Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study)
作者：Juan P Frias, Manige Konig* (Velocity Clinical Research, USA; Eli Lilly, USA)

（二）12 August 2023 - Volume 402 - Issue 10401（2023年8月12日第402卷第10401期）
https://www.thelancet.com/journals/lancet/issue/vol402no10401/PIIS0140-6736(23)X0032-4

COMMENT（评论）
1.针对2型糖尿病的新型降糖疗法：肠促胰素领域的最新发展
(A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena)
作者：Stephen C Bain* (Swansea Bay University Health Board and Swansea University Medical School, UK)

2.Janus激酶在幼年特发性关节炎中的抑制作用
(Janus kinase inhibition in juvenile idiopathic arthritis)
作者：Eileen C Rife, Randy Q Cron* (Division of Rheumatology, Children's Hospital of Alabama, University of Alabama at Birmingham, USA)

ARTICLES（文章）
3.Retatrutide，一种用于2型糖尿病患者的GIP，GLP-1和胰高血糖素受体激动剂：在美国进行的一项随机，双盲，安慰剂和阳性对照，平行组，2期试验
(Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA)
作者：Julio Rosenstock, Tamer Coskun* (Velocity Clinical Research at Medical City, USA;Eli Lilly and Company, USA)

4.巴瑞替尼治疗幼年特发性关节炎：一项国际、3期、随机、双盲、安慰剂对照、戒断、疗效和安全性试验
(Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial)
作者：Athimalaipet V Ramanan (Bristol Royal Hospital for Children and Translational Health Sciences, University of Bristol, UK)

（三）19 August 2023 - Volume 402 - Issue 10402（2023年8月19日第402卷第10402期）
https://www.thelancet.com/journals/lancet/issue/vol402no10402/PIIS0140-6736(23)X0033-6

COMMENT（评论）
1.SURMOUNT-2：替尔泊肽治疗肥胖2型糖尿病的新进展
(SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide)
作者：Christian Seerup Frandsen* (Department of Gynaecology, Rigshospitalet, University of Copenhagen, Denmark)

2.接受嵌合抗原受体治疗复发性慢性淋巴细胞白血病
(Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia)
作者：Manali Kamdar* (Division of Hematology, The University of Colorado Anschutz Medical Campus, USA)

ARTICLES（文章）
3.替尔泊肽每周一次用于治疗2型糖尿病患者的肥胖症（SURMOUNT-2）：一项双盲、随机、多中心、安慰剂对照的3期试验
(Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial)
作者：W Timothy Garvey* (UAB Diabetes Research Center, University of Alabama at Birmingham, USA)

4.在印度，通过营养补充以预防肺结核患者家庭接触者的结核病发病率（RATIONS）：一项基于现场、开放标签、集群随机、对照的试验
(Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial)
作者：Anurag Bhargava* (Department of Medicine, Yenepoya Medical College, Canada)

5.Lisocabtagene maraleucel治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤（TRANSCEND CLL 004）：一项多中心、开放标签、单臂、1-2期研究
(Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study)
作者：Tanya Siddiqi (Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, USA)

（四）26 August 2023 - Volume 402 - Issue 10403（2023年8月26日第402卷第10403期）
https://www.thelancet.com/journals/lancet/issue/vol402no10403/PIIS0140-6736(23)X0034-8

COMMENT（评论）
1.继续探寻司美格鲁肽在2型糖尿病患者中的最佳剂量
(The pursuit of optimal semaglutide dosing in type 2 diabetes continues)
作者：Christina H Sherrill* (Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, USA)

2.口服司美格鲁肽：注射剂中的绿洲
(Oral semaglutide: an OASIS from injectables)
作者：Priya Manjoo* (Endocrinology and Metabolism, Department of Medicine, Division of Endocrinology, University of British Columbia, Canada)

CORRESPONDENCE（通信）
3.奥密克戎中和：RBD-二聚体加强剂与BF.7和BA.5.2突破性感染的比较
(Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection)
作者：Lianpan Dai,George F Gao* (Institute of Microbiology of the Chinese Academy of Sciences, China)

ARTICLES（文章）
4.成人2型糖尿病（PIONEER PLUS）患者中每日一次口服司美格鲁肽25mg和50mg与14mg的有效性和安全性比较：一项多中心、随机、3b期试验
(Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial)
作者：Vanita R Aroda* (Department of Medicine, Division of Endocrinology, Diabetes & Hypertension, Brigham and Women's Hospital, Harvard Medical School, USA)

5.超重或肥胖成人每天口服一次司美格鲁肽50mg（OASIS 1）：一项随机、双盲、安慰剂对照的3期试验
(Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial)
作者：Filip K Knop* (Centre for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Denmark)

6.cagrilintide2.4mg与司美格鲁肽2.4mg每周一次联合用药治疗2型糖尿病的疗效和安全性：一项多中心，随机，双盲，阳性对照，2期试验
(Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial)
作者：Juan P Frias* ( Velocity Clinical Research, USA)

三、新英格兰医学杂志（2023年8月第389卷第5-9期）
（一）3 August 2023 - Volume 389 - No 5（2023年8月3日第389卷第5期）
https://www.nejm.org/toc/nejm/389/5

ORIGINAL ARTICLES（原创文章）
1.VX-548选择性抑制NaV1.8用于治疗急性疼痛
(Selective Inhibition of NaV1.8 with VX-548 for Acute Pain)
作者：Jim Jones* (Vertex Pharmaceuticals, USA)

2.双相I型抑郁症的辅助抗抑郁维持时间
(Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression)
作者：Lakshmi N. Yatham* (the University of British Columbia, Canada)

EDITORIALS（社论）
3.靶向外周钠通道治疗疼痛
(Targeting a Peripheral Sodium Channel to Treat Pain)
作者：Stephen G. Waxman (the Departments of Neurology, Neuroscience, and Pharmacology, Yale School of Medicine, USA)

CORRESPONDENCE（通信）
4.卡博替尼联合纳武利尤单抗和伊匹木单抗治疗肾细胞癌
(Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma)

（二）10 August 2023 - Volume 389 - No 6（2023年8月10日第389卷第6期）
https://www.nejm.org/toc/nejm/389/6

ORIGINAL ARTICLES（原创文章）
1.帕博利珠单抗可用于早期非小细胞肺癌的围手术期
(Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer)
作者：Heather Wakelee* (Stanford University School of Medicine, Stanford Cancer Institute, USA)

2.在非小细胞肺癌III期患者中，纳武利尤单抗联合化疗的围手术期治疗
(Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer)
作者：Mariano Provencio* (the Medical Oncology Department, Hospital Universitario Puerta de Hierro, Spain)

3.三重激素受体激动剂Retatrutide治疗肥胖症—一项2期试验
(Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial)
作者：Ania M. Jastreboff* (the Yale University School of Medicine (Endocrinology and Metabolism), USA)

IMAGES IN CLINICAL MEDICINE（临床医学影像）
4.慢性呋喃妥因引起的肺损伤
(Chronic Nitrofurantoin-Induced Lung Injury)
作者：Vidisha Master (Rochester General Hospital, USA)

EDITORIALS（社论）
5.三G受体激动剂——肥胖的本垒打？
(Triple G Agonists — A Home Run for Obesity?)
作者：Mary Elizabeth Patti (Joslin Diabetes Center, USA)

CORRESPONDENCE（通信）
6.马里和冈比亚的脑膜炎球菌疫苗
(Meningococcal Vaccine in Mali and Gambia)

（三）17 August 2023 - Volume 389 - No 7（2023年8月17日第389卷第7期）
https://www.nejm.org/toc/nejm/389/7

ORIGINAL ARTICLES（原创文章）
1.Vorasidenib用于治疗IDH1或IDH2突变型低级别胶质瘤
(Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma)
作者：Patrick Y. Wen¹, Timothy F. Cloughesy², Ingo K. Mellinghoff³* (1. Dana–Farber Cancer Institute, USA; 2. the University of California, USA; 3. Memorial Sloan Kettering Cancer Center, USA)

CORRESPONDENCE（通信）
2.氢化可的松治疗重症社区获得性肺炎
(Hydrocortisone in Severe Community-Acquired Pneumonia)

3.利福喷汀在麻风病患者家庭接触者中的应用
(Rifapentine in Household Contacts of Patients with Leprosy)

（四）24 August 2023 - Volume 389 - No 8（2023年8月24日第389卷第8期）
https://www.nejm.org/toc/nejm/389/8

ORIGINAL ARTICLES（原创文章）
1.匹伐他汀预防HIV感染的心血管疾病
(Pitavastatin to Prevent Cardiovascular Disease in HIV Infection)
作者：Steven K. Grinspoon* (the Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, USA)

2.在KRAS G12C突变的实体瘤中，Divarasib（GDC-6036）单药治疗的应用
(Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation)
作者：Adrian Sacher¹*, Patricia LoRusso², Manish R. Patel³ (1. the Princess Margaret Cancer Centre, Canada; 2. Yale Cancer Center, Yale University, USA; 3. Florida Cancer Specialists/Sarah Cannon Research Institute,  Spain)

3.乌干达疟疾寄生虫对青蒿素部分耐药性的演变
(Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda)
作者：Melissa D. Conrad* ( University of California, USA)

CORRESPONDENCE（通信）
4.抗胰岛素受体抗体治疗恶性胰岛素瘤和难治性低血糖
(Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia)
作者：Soravis Osataphan (Beth Israel Deaconess Medical Center, USA)

（五）31 August 2023 - Volume 389 - No 9（2023年8月31日第389卷第9期）
https://www.nejm.org/toc/nejm/389/9

ORIGINAL ARTICLES（原创文章）
1.Concizumab联合抑制剂治疗血友病的3期试验
(Phase 3 Trial of Concizumab in Hemophilia with Inhibitors)
作者：Tadashi Matsushita* (the Department of Transfusion Medicine, Nagoya University Hospital, Japan)

2.通过CRISPR-Cas9编辑HBG1和HBG2启动子治疗镰状细胞病
(CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease)
作者：Akshay Sharma (the Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, USA)

四、美国医学会杂志（2023年8月第330卷第5-8期）
（一）1 August 2023 -Volume 330 - No.5（2023年8月1日第330卷第5期）
https://jamanetwork.com/journals/jama/issue/330/5

Evidence Report（循证报告）
1.补充叶酸以预防神经管缺陷：美国预防服务工作组的最新证据报告和系统综述
(Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force)
作者：Meera Viswanathan* (RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center, USA)

Editorial（社论）
2.充分有效的叶酸强化
(Fully Effective Folic Acid Fortification)
作者：Joan K. Morris (PHRI, St George’s University of London, UK)

3.重申补充叶酸的建议：历史往复
(Reaffirming Recommendations for Folic Acid Supplementation: Everything Old Is New Again)
作者：David B. Nelson (Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, USA)

Medical News in Brief（医学新闻简讯）
4.在缓解背痛方面，阿片类药物与安慰剂并无更多优势
(Opioids No Better Than Placebo at Relieving Back Pain)
作者：Emily Harris

Comment & Response（评论与回复）
5.使用靶向治疗或高强度他汀类药物治疗冠状动脉疾病
(Treating Coronary Artery Disease With Treat-to-Target or High-Intensity Statin)
作者：Tomoyuki Kawada ( Department of Hygiene and Public Health, Nippon Medical School, Japan)

6.使用靶向治疗或高强度他汀类药物治疗冠状动脉疾病——作者回复
(Treating Coronary Artery Disease With Treat-to-Target or High-Intensity Statin—Reply)
作者：Sung-Jin Hong (Severance Hospital, Yonsei University College of Medicine, South Korea)

7.治疗剂量肝素对COVID-19住院患者的治疗效果
(Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19)
作者：Bruce L. Davidson (Washington State University Floyd College of Medicine, USA)

8.治疗剂量肝素对COVID-19住院患者的治疗效果——作者回复
(Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19—Reply)
作者：Ewan C. Goligher (Interdepartmental Division of Critical Care Medicine, University of Toronto, Canada)

（二）8 August 2023 -Volume 330 - No.6（2023年8月8日第330卷第6期）
https://jamanetwork.com/journals/jama/issue/330/6

Original Investigation（原始调查）
1.多奈单抗在早期症状性阿尔茨海默病中的应用：TRAILBLAZER-ALZ2随机临床试验
(Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial)
作者：John R. Sims (Eli Lilly and Company, Indiana)

2.阿托伐他汀治疗蒽环类药物相关性心功能不全：STOP-CA随机临床试验
(Atorvastatin for Anthracycline-Associated Cardiac Dysfunction:The STOP-CA Randomized Clinical Trial)
作者：Tomas G. Neilan (Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, USA)

Research Letter（研究信）
3.美国疗养院SARS-CoV-2感染的单克隆抗体和口服抗病毒治疗
(Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes)
作者：Brian E. McGarry (Department of Medicine, University of Rochester, USA)

Editorial（社论）
4.针对阿尔茨海默病的淀粉样蛋白靶向单克隆抗体
(Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease)
作者：Gil D. Rabinovici (Memory & Aging Center, Department of Neurology, University of California San Francisco, USA)

5.多奈单抗治疗阿尔茨海默病——谁受益，谁受伤？
(Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?)
作者：Jennifer J. Manly (Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Department of Neurology, Columbia University Irving Medical Center, USA)

Medical News in Brief（医学新闻简讯）
6.阿尔茨海默病药物仑卡奈单抗获得惯例FDA批准
(Alzheimer Drug Lecanemab Gains Traditional FDA Approval)
作者：Emily Harris

（三）15 August 2023 -Volume 330 - No.7（2023年8月15日第330卷第7期）
https://jamanetwork.com/journals/jama/issue/330/7

Original Investigation（原始调查）
1.妊娠30-34周产前静脉注射镁与后代神经发育结果的关系：MAGENTA随机临床试验
(Prenatal Intravenous Magnesium at 30-34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial)
作者：Caroline A. Crowther (Liggins Institute, University of Auckland, New Zealand)

2.围手术期阴道雌激素辅助原生组织阴道根尖脱垂修复：一项随机临床试验
(Perioperative Vaginal Estrogen as Adjunct to Native Tissue Vaginal Apical Prolapse Repair:A Randomized Clinical Trial)
作者：David D. Rahn (Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, USA)

Editorial（社论）
3.生产时使用镁制剂用于神经保护：重新审视胎龄标准
(Intrapartum Magnesium for Neuroprotection:Revisiting Gestational Age Criteria)
作者：Judette Marie Louis (Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, USA)

Medical News in Brief（医学新闻简讯）
4.FDA批准首个非处方口服避孕药
(FDA Greenlights First Over-the-Counter Oral Birth Control)
作者：Emily Harris

5.FDA批准用于婴幼儿的RSV单克隆抗体
(FDA Approves RSV Monoclonal Antibody for Infants and Young Children)
作者：Emily Harris

（四）22/29 August 2023 -Volume 330 - No.8（2023年8月22/29日第330卷第8期）
https://jamanetwork.com/journals/jama/issue/330/8

Recommendation Statement（建议声明）
1.预防HIV感染的暴露前预防：美国预防服务工作组建议声明
(Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement)
作者：US Preventive Services Task Force

Evidence Report（循证报告）
2.预防HIV感染的暴露前预防：美国预防服务工作组的最新证据报告和系统综述
(Preexposure Prophylaxis for the Prevention of HIV:Updated Evidence Report and Systematic Review for the US Preventive Services Task Force)
作者：Roger Chou (The Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland)

Medical News in Brief（医学新闻简讯）
3.食欲素激动剂在发作性睡病试验中有效但不安全
(Orexin Agonist Effective but Not Safe in Narcolepsy Trial)
作者：Emily Harris

五、自然：药物发现综述（2023年8月第22卷）
https://www.nature.com/nrd/volumes/22/issues/8

News（新闻）
1.个体化癌症疫苗通过首次重大临床试验
(Personalized cancer vaccines pass first major clinical test)
作者：Elie Dolgin

Article（文章）
2.抗体-药物偶联物在肿瘤学中成熟
(Antibody–drug conjugates come of age in oncology)
作者：Charles Dumontet* (University of Lyon, Hospices Civils de Lyon, France)

六、自然：免疫学综述（2023年8月第23卷第8期）
August 2023 - Volume 23 - Issue 8 （2023年8月第23卷第8期）
https://www.nature.com/nri/volumes/23/issues/8

略

七、柳叶刀：呼吸医学（2023年8月）
August 2023 - Volume 11 - Number 8 （2023年8月第11卷第8期）
https://www.thelancet.com/journals/lanres/issue/vol11no8/PIIS2213-2600(23)X0008-3

Article（文章）
1.在儿童和青少年中口服雾化或肌内注射Ad5-nCoV疫苗和灭活疫苗（BBIBP-CorV或CoronaVac）异源加强接种的安全性和免疫原性：一项随机、开放标签、平行对照、非劣效性、单中心研究
(Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study)
作者：Tao Huang¹, Sheng Zhang², De-Fang Dai¹, Bu-Sen Wang³, Lu Zhuang², Hai-Tao Huang⁴, Zhong-Fang Wang⁵, Jin-Bo Gou⁴*, Li-Hua Hou³*, Li-Dong Gao¹*, Zhi-Chun Feng²* (1. Hunan Provincial Center for Disease Control and Prevention, China; 2. Faculty of Pediatrics, Chinese PLA General Hospital, China; 3. Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China; 4. CanSino Biologics, China; 5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, China)

八、英国医学期刊（2023年8月第382卷第8394-8395期）
（一）05 August 2023 - Volume 382 - Issue 8394（2023年8月5日第382卷第8394期）
https://www.bmj.com/content/382/8394

Research（研究）
1.产前皮质类固醇与儿童严重感染风险的关系：全国性队列研究
(Association between antenatal corticosteroids and risk of serious infection in children: nationwide cohort study)
作者：Tsung-Chieh Yao* (Division of Allergy, Asthma, and Rheumatology, Department of Paediatrics, Chang Gung Memorial Hospital, Taiwan, China)

2.产前早期暴露于皮质类固醇后的足月或晚期早产儿比例和结局：160万婴儿的系统评价和meta分析
(The proportions of term or late preterm births after exposure to early antenatal corticosteroids, and outcomes: systematic review and meta-analysis of 1.6 million infants)
作者：Kiran Ninan, Sarah D McDonald* (Department of Health Research Methods, Evidence, and Impact, McMaster University, Canada)

Editorials（社论）
3.产前皮质类固醇和长期结局
(Antenatal corticosteroids and longer term outcomes)
作者：Jessica Kimpton¹, David J Cox² (1. London Deanery, UK; 2. Great Ormond Street Hospital for Children NHS Foundation Trust, UK)

Comment（评论）
4.糖尿病的患病风险与他汀类药物：比较苹果与橙子
(Risk of diabetes with statins: comparing apples with oranges)
作者：Ben Braithwaite (East Ham Care Centre, UK)

（二）19 August 2023 - Volume 382 - Issue 8395（2023年8月19日第382卷第8395期）
https://www.bmj.com/content/382/8395

Feature（专题）
1.我们如何最佳使用Paxlovid和其他抗covid病毒药物？
(How do we best use Paxlovid and other covid antivirals?)
作者：Katharine Lang

Comment（评论）
2.绝经期激素治疗和痴呆：因果关系仍不确定，而非不可能
(Menopausal hormone therapy and dementia: causal link remains uncertain rather than unlikely)
作者：Nelsan Pourhadi* (Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Denmark)

3.阿片类药物使用障碍：舒芬太尼是否会让历史重演?
(Opioid use disorder: is history repeating itself with sufentanil?)
作者：J Wilson Carswell*

九、自然：医学（2023年8月第29卷第8期）
August 2023 - Volume 29 - Issue 8（2023年8月第29卷第8期）
https://www.nature.com/nm/volumes/29/issues/8

NEWS（新闻）
1.Efruxifermin联合GLP-1受体激动剂可减少NASH患者的肝脏脂肪
(Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH)
作者：Thiago Carvalho*

2.抗CD40L抗体frexalimab可减缓多发性硬化症患者的新发脑病变
(Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis)
作者：Thiago Carvalho*

Correspondence（通信）
3.针对猴痘抗病毒药物的国际统一研究是未来流行病的蓝图
(The international Unity study for antivirals against mpox is a blueprint for future epidemics)
作者：Erica Telford¹, Alexandra Calmy²* (1. ANRS|Emerging Infectious Diseases/Inserm, Franc; 2. HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Switzerland)

News & Views（新闻与观点）
4.裸盖菇素治疗神经性厌食症
(Psilocybin for the treatment of anorexia nervosa)
作者：Tomislav Majić, Stefan Ehrlich* (Department of Psychiatry and Psychotherapy, Berlin Institute of Health, Germany; Division of Psychological and Social Medicine and Developmental Neurosciences, Translational Developmental Neuroscience Section, Faculty of Medicine, Technische Universität Dresden, Germany)

Article（文章）
5.达雷妥尤单抗单药治疗难治性狼疮性肾炎
(Daratumumab monotherapy for refractory lupus nephritis)
作者：Dario Roccatello*, Roberta Fenoglio (University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member), Italy)

6.阿得贝利单抗在局部晚期可切除食管鳞状细胞癌中的新辅助治疗：1b期试验
(Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial)
作者：Jun Yin¹, Jingnan Yuan², Qing Zhou²*, Kui Wu²*, Lijie Tan¹* (1. Department of Thoracic Surgery, Cancer Center, Zhongshan Hospital of Fudan University, China; 2. HIM-BGI Joint Lab, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, BGI-Hangzhou, China)

7.一线吡咯替尼治疗晚期HER2突变非小细胞肺癌：一项以患者为中心的2期试验
(First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial)
作者：Si-Yang Maggie Liu¹, Hai-Yan Tu², Xue-Wu Wei², Yangqiu Li¹*, Qing Zhou²*, Yi-Long Wu²* (1. Department of Hematology, The First Affiliated Hospital, Jinan University, China; 2. Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, China)

8.一线度伐利尤单抗和tremelimumab联合化疗RAS突变转移性结直肠癌：1b/2期试验
(First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial)
作者：Marion Thibaudin*, François Ghiringhelli*, Caroline Truntzer* (Université Bourgogne Franche-Comté, France)

9.曲妥珠单抗deruxtecan治疗HER2表达可变的转移性乳腺癌：2期DAISY试验
(Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial)
作者：Fernanda Mosele, Fabrice André* (Department of Medical Oncology, Gustave Roussy, France)

10.佐妥昔单抗联合CAPOX治疗CLDN18.2阳性胃癌或胃食管交界处腺癌：随机3期GLOW试验
(Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial)
作者：Manish A. Shah, Rui-Hua Xu* (Weill Cornell Medical College, USA; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, China)

十、世界精神病学（2023年第22卷第2期）
（一）2023 - Volume 22 - Issue 2（2023年第22卷第2期）
https://onlinelibrary.wiley.com/toc/20515545/2023/22/2

略